SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is currently a major talking point after its recent earnings report, which, despite showing subscriber growth and exceeding revenue expectations, led to a notable sell-off. Community discussion is split between those viewing the price dip as an overreaction and a long-term buying opportunity, and those concerned about the cautious forward guidance, valuation, and the strategic implications of the potential Warner Bros. Discovery acquisition.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is trending as reports indicate the U.S. government is establishing a new digital asset reserve to hold seized Bitcoin, shifting from prior selling policies and removing market pressure. This comes amidst heightened market volatility, which many in the community attribute to political rhetoric and broader macroeconomic concerns. Investor sentiment remains sharply divided, with intense debate around Bitcoin's role as a digital safe haven compared to traditional assets like gold and silver, while closely watching key technical support levels.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending significantly after Chairman Ryan Cohen increased his stake by purchasing an additional 500,000 shares, which the community views as a powerful signal of confidence. This insider move has ignited fervent speculation about upcoming strategic developments, further reinforced by the stock's notable resilience and positive performance even on days when the broader market is declining.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPY is trending amidst discussions surrounding President Trump's escalating rhetoric on acquiring Greenland, which includes threats of tariffs against opposing nations. This has sparked concerns over US government finances and international relations, with some European entities reportedly divesting from US Treasuries. Community sentiment is deeply divided, with many anticipating further market volatility and a potential "Sell America" trend, while others view the current downturn as an overreaction and a "buy the dip" opportunity.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending lower as market sentiment reacts sharply to former President Trump's threats of new tariffs against European allies concerning Greenland. This has ignited a lively debate within the community, with some anticipating a deeper market correction amid broader bond market jitters, while others expect a "buy the dip" rebound, confident in the underlying strength of the tech sector despite geopolitical noise.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN Limited is seeing significant investor attention driven by its strategic pivot from Bitcoin mining to becoming a leading AI cloud infrastructure provider. The company's substantial power capacity and recent $9.7 billion Microsoft GPU cloud contract position it as a critical player in meeting the surging demand for AI compute. Community chatter highlights optimism for further hyperscaler partnerships and long-term growth, with many viewing IREN as undervalued despite market fluctuations.

Ondas Holdings, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Holdings Inc

Ondas Holdings is trending following a recent investor day that revealed significantly raised revenue targets and a substantial increase in backlog, prompting multiple analyst upgrades with considerably higher price targets. The community is buzzing about Ondas's strategic pivot to autonomous defense infrastructure, with many asserting the market has yet to fully price in its combat-proven technology and robust financial position. Investors are closely monitoring the integration of acquired assets and potential for major contract announcements in the rapidly evolving drone and counter-drone sectors.

Corvus Pharmaceuticals, Inc. engages in the development of immune modulator product candidates with the potential to treat solid cancers, T-cell lymphomas, autoimmune diseases, and infectious diseases. Its product pipeline includes B Cell Activator and Anti-CD73, Adenosine Production Inhibitor Anti-CD73, ITK Inhibitor, A2AR Inhibitor, Anti-CXCR2, and A2BR Inhibitor. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals is actively trending following its announced proposed public offering of common stock and warrants, which comes on the heels of an earlier surge driven by positive Phase 1 clinical trial data for its atopic dermatitis drug. The community is sharply divided, with many debating potential dilution and a subsequent price correction, while others view the offering as a strategic capital raise to advance a promising pipeline in a large market. This highlights the inherent tension for clinical-stage biotechs, balancing funding needs with encouraging early-stage therapeutic developments.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending amidst heightened market uncertainty driven by recent tariff threats related to international trade and escalating geopolitical tensions. Community discussions are focused on the potential for increased volatility and the broader implications of global instability on established market leaders, with some anticipating significant market corrections while others look for buying opportunities.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

Newegg Commerce is trending as significant insider share accumulation has reportedly locked up much of its free float, coinciding with rising demand for PC components and AI hardware. The community is intensely discussing perceived aggressive short-seller tactics and "phantom shares" that appear to be suppressing the price on remarkably low volume. This situation is fueling strong investor convictions who anticipate an eventual, explosive short squeeze.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Femasys (NASDAQ:FEMY) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Femasys from a "sell" rating to a "hold" rating in a research note on Friday...

<ul class="summary-bullets"><li>The stake sale comes on the heels of the company increasing its stake in TNF Pharmaceuticals in September by an additional $3 million.&nbsp;</li><li>PharmaCyte said that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.&nbsp;</li><li>The company said that monetizing its stake in Femasys will help strengthen its financial position.</li></ul> PharmaCyte Biotech, Inc. (PMCB) said on Tuesday that it sold its stake in Femasys Inc. (FEMY), thereby increasing its cash and marketable securities to about $20 million.The company had cash and marketable securities of only about $13.3 million as of the end of July. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pharmacyte.com/press-releases/detail/319/pharmacyte-biotech-successfully-monetizes-femasys-stake">said</a> that monetizing its stake in Femasys will help strengthen its financial position.Shares of <a href="https://stocktwits.com/symbol/PMCB">PMCB </a>traded 25% higher at the time of writing.<h2 class="st-heading-2">PharmaCyte’s Financial Position</h2>CEO Josh Silverman stated that the successful monetization of the Femasys position demonstrates the effectiveness of the strategic and disciplined capital allocation approach. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation,” he said.Overall, PharmaCyte now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash. The company highlighted its low stock price below $1 and added that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.The stake sale comes on the heels of the company increasing its stake in Q/C Technologies, formerly known as TNF Pharmaceuticals, in September by an additional $3 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PMCB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the news shows the company has ways to generate cash without doing share offerings.<stembedurl>https://stocktwits.com/MadBat/message/637404061</stembedurl>Another expects the stock to cross the $1 threshold.<stembedurl>https://stocktwits.com/cbt2020/message/637412358</stembedurl>PMCB stock fell 48% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-slips-after-q4-revenue-guidance-disappoints/cL52NcEREgI">Nio Stock Slips After Q4 Revenue Guidance Disappoints</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.

Equity

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.


<ul class="summary-bullets"><li>Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.</li><li>The company raised $12 million through convertible notes, with potential total proceeds of $58 million if all warrants are exercised, strengthening its balance sheet.</li><li>Retail investors on Stocktwits turned bullish on the news, calling Femasys a long-term play with disruptive potential in women’s health.</li></ul>Retail chatter around Femasys spiked on Monday following the company’s announcement that it secured U.S. Food and Drug Administration (FDA) approval to advance the final phase of its pivotal trial for FemBloc, a non-surgical permanent birth control device, and raised $12 million in financing that could grow to $58 million if all warrants are exercised.<h2 class="st-heading-2">FDA Clears Final Phase Of FemBloc Trial</h2>Femasys announced FDA approval to resume enrollment for the final phase of the FemBloc pivotal FINALE trial, allowing it to move closer to U.S. Pre-Market Approval (PMA).The Investigational Device Exemption (IDE) approval came following the successful completion of the trial’s first stage, advancing the commercialization of the world’s first non-surgical, permanent birth control in the U.S.FemBloc uses a polymer-based delivery system that blocks the fallopian tubes without incisions or anesthesia, offering a safer and lower-cost alternative to surgical sterilization.<h2 class="st-heading-2">Financing Deal With Potential Upside To $58 Million</h2>Alongside the FDA update, Femasys entered into a private placement agreement with institutional and accredited investors, led by Jorey Chernett, to issue $12 million in senior secured convertible notes and warrants,&nbsp;with the potential to raise total proceeds to $58 million if exercised for cash.The company said proceeds will go toward refinancing debt and advancing&nbsp;the commercialization of its fertility and permanent birth control portfolio.The notes carry an 8.5% annual interest rate and are convertible at $0.73 per share, a 15% premium to the stock’s prior closing price. Warrants carry exercise prices between $0.81 and $1.10 per share, with 10-year terms.<h2 class="st-heading-2">Stocktwits Users Cheer Regulatory Win</h2>On Stocktwits, retail sentiment for Femasys was ‘bullish’ amid ‘extremely high’ message volume.<figure class="image"><img style="aspect-ratio:969/142;" src="https://news.stocktwits-cdn.com/femy_ss_jpg_e7ab6d375e.webp" alt="femy ss.jpg" width="969" height="142"><figcaption>FEMY sentiment and message volume as of November 3 | Source: Stocktwits</figcaption></figure>One user said they viewed Femasys as a long-term play, describing its regulatory progress and disruptive women’s health products as strong growth drivers. The user added that the company’s performance is likely to move “based on fundamentals” rather than hype, noting that women’s health remains an underappreciated sector.<stembedurl>https://stocktwits.com/CoconutNinja/message/634760377</stembedurl>Another user speculated whether the stock would see after-hours upside following the positive news.<stembedurl>https://stocktwits.com/steve04240/message/634739416</stembedurl><a href="https://stocktwits.com/symbol/FEMY">Femasys’ stock</a> has declined 40% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Femasys logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Femasys Stock Sparks Retail Frenzy After FDA Clears Final Phase Of FemBloc Trial And $58M Financing

Femasys secured FDA approval to proceed with the final phase of its pivotal FemBloc trial, a key step toward U.S. market approval for its non-surgical permanent birth control device.

Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates

Femasys (FEMY) delivered earnings and revenue surprises of +11.11% and -48.88%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Precision BioSciences (DTIL) Reports Q2 Loss, Lags Revenue Estimates

Precision BioSciences (DTIL) delivered earnings and revenue surprises of -2,266.67% and -99.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Lags Revenue Estimates

Vir Biotechnology (VIR) delivered earnings and revenue surprises of -11.11% and -84.12%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Shares of Femasys Inc. (FEMY) traded 17% lower on Friday morning after the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/05/30/3091024/0/en/Femasys-Announces-Pricing-of-Underwritten-Public-Offering-and-Concurrent-Private-Placement-with-Gross-Proceeds-of-4-5-Million.html">announced</a> the pricing of an underwritten public offering of 3.6 million shares of its common stock at $0.85 per share.The offer price represents a discount of about 17% from the stock’s closing price on Thursday.The company also announced a separate concurrent private placement of approximately 1.7 million shares of its common stock at the same price as sold to certain existing institutional stockholders of Femasys, as well as a price of $1.02 per share to certain of its directors and officers.The gross proceeds of the public offering and private placement to Femasys are expected to be about $4.5 million.The company stated that it intends to use the net proceeds for the expansion of its commercial efforts, the development of its products and product candidates, general corporate purposes, capital expenditures, working capital, and general and administrative expenses.Both the public offering and the private placement are expected to close on or about June 2 and are subject to the successful completion of customary closing conditions.On Stocktwits, the retail sentiment around Femasys jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume rose from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:627/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_8_59_37_AM_png_3daa1e0a3d.webp" alt="FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits" width="627" height="64"><figcaption>FEMY's Sentiment Meter and Message Volume as of 9:00 a.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user expressed optimism about the company and said they will buy shares in the short term.<stembedurl>https://stocktwits.com/Mirto/message/616299906</stembedurl>Another user, however, expressed concerns about the stock falling below $1.<stembedurl>https://stocktwits.com/goldenxb/message/616299012</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY stock</a> is down by over 23% this year and by about 28% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/nvidia-dell-to-build-doe-s-doudna-supercomputer/ch0MD6bRbuG">Nvidia, Dell To Build DOE’s Doudna Supercomputer – ‘Time Machine for Science,’ Says Jensen Huang</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up

The offer price of $0.85 represents a discount of about 17% from the stock’s closing price on Thursday.

Femasys Inc. (FEMY) Reports Q1 Loss, Misses Revenue Estimates

Shares of Femasys Inc. (FEMY) tumbled nearly 14% on Thursday after the company’s 2024 <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.femasys.com/news/news-details/2025/Femasys-Announces-Financial-Results-for-Year-Ended-December-31-2024-and-Provides-Corporate-Update/default.aspx">earnings</a> fell below Wall Street estimates.The company reported a 52% jump in annual sales to $1.62 million compared to 2023, but failed to meet an analyst estimate of $2.71 million, according to FinChat data.The loss per share of $0.85, though lower than the $0.93 reported in 2023, exceeded an estimated loss of $0.80.The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.Femasys said its current cash and cash equivalents, which includes approximately $5.4 million raised subsequent to year-end, will be sufficient to fund its ongoing operations into third quarter of 2025.The company focuses on addressing critical unmet needs in women’s health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products.Femasys CEO Kathy Lee-Sepsick said that the company is focused on commercializing FemaSeed, its first-line infertility treatment, and expects U.S. revenue to increase by about 50% in the first quarter of 2025 compared to the previous quarter.“We are continuing to advance our FemBloc to commercialization in Europe while executing on the clinical pivotal trial for U.S. FDA approval,” she added. FemBloc is the company's non-surgical permanent birth control.On Stocktwits, retail investor sentiment about Femasys dropped slightly in the ‘bullish’ territory (56/100) while message volume dropped from ‘high’ to ‘normal’ over the past 24 hours.<figure class="image"><img style="aspect-ratio:651/151;" src="https://news.stocktwits-cdn.com/Screenshot_2025_03_27_at_1_54_06_PM_png_ca980a7546.webp" alt="FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits" width="651" height="151"><figcaption>FEMY's Sentiment Meter and Message Volume as of 2:05 p.m. ET on March 27, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user noted the company’s increase in annual sales and opined that the company is “heading in the right direction for sure.”<stembedurl>https://stocktwits.com/stoneblood/message/609410856</stembedurl>Another user highlighted they were buying the stock.<stembedurl>https://stocktwits.com/Mirto/message/609411502</stembedurl><a href="https://stocktwits.com/symbol/FEMY">FEMY shares</a> have gained over 19% this year but have lost nearly 11% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/microalgo-stock-surges-after-wimi-hologram-cloud-expands-stake/chJ2ah6RbEB">MicroAlgo Stock Surges After WiMi Hologram Cloud Expands Stake, Locking In Shares For 10 Years – Retail Hopes For Another Rally</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Femasys Reports Wider-Than-Expected Annual Loss, But Retail Continues To Be Optimistic

The company said that as of the end of 2024, it had an accumulated deficit of $127.2 million and cash and cash equivalents of only $3.5 million.

Femasys, Inc. is a biomedical company, which engages in the development of novel solutions for reproductive healthcare. The company was founded by Kathy Lee-Sepsick in 2004 and is headquartered in Suwanee, GA.

Femasys Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

Current Price	$0.6787
Prev Close	$0.6505
Open	$0.675
Dividend Yield	0.00%
50-Day Moving Average	$0.7924
Beta	0.87
Avg. Volume	1.54M
PE Ratio	-0.90

52-Week High	$1.80
52-Week Low	$0.3067
Market Capitalization	$38.78M
EPS (Annual)	-$0.845
Price to Book	6.75
Revenue Per Employee	$22,945.18
Enterprise Value/EBITDA	N/A

FEMY
Femasys Inc

Feed

News

Sentiment

Fundamentals

Info

Latest FEMY News

FEMYFemasys Inc